Jonathan Kay to Infliximab
This is a "connection" page, showing publications Jonathan Kay has written about Infliximab.
Connection Strength
2.432
-
Baker JF, Leonard CE, Lo Re V, Weisman MH, George MD, Kay J. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. Arthritis Rheumatol. 2020 07; 72(7):1067-1071.
Score: 0.684
-
Lambert J, Wyand M, Lassen C, Shneyer L, Thomson E, Knight A, Willers J, Kay J. Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. Int J Clin Pharmacol Ther. 2016 Apr; 54(4):315-22.
Score: 0.515
-
Kay J, Bock AE, Rehman M, Zhang W, Zhang M, Iikuni N, Alvarez DF. Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis. RMD Open. 2022 09; 8(2).
Score: 0.201
-
Curtis JR, Xie F, Kay J, Kallich JD. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis. Arthritis Res Ther. 2019 12 12; 21(1):285.
Score: 0.166
-
Kay J. A 'wind of change' to biosimilars: The NOR-SWITCH trial and its extension. J Intern Med. 2019 06; 285(6):693-695.
Score: 0.159
-
Kay J, D?rner T, Emery P, Kvien TK, Breedveld FC. Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar. Ann Rheum Dis. 2020 04; 79(4):e44.
Score: 0.156
-
Kay J, Winthrop KL. Pharmacotherapy: Biosimilar switching - "To set a form upon desired change". Nat Rev Rheumatol. 2017 07; 13(7):391-392.
Score: 0.140
-
Kay J, Isaacs JD. Clinical trials of biosimilars should become more similar. Ann Rheum Dis. 2017 01; 76(1):4-6.
Score: 0.132
-
D?rner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015 Dec; 11(12):713-24.
Score: 0.123
-
Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis. 2013 Oct; 72(10):1589-93.
Score: 0.107
-
Smolen JS, Kay J, Matteson EL, Landew? R, Hsia EC, Xu S, Zhou Y, Doyle MK. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis. 2014 Oct; 73(10):1811-8.
Score: 0.027
-
Smolen JS, Kay J, Doyle MK, Landew? R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009 Jul 18; 374(9685):210-21.
Score: 0.020